Digoxin detailed information

Digoxin detailed information

Clinical data
Pregnancy category	A (Au), C (U.S.)
Routes of administration	Oral, Intravenous
ATC code	C01AA02 (WHO) C01AA05 (WHO) C01AA08 (WHO)
Legal status
Legal status	S4 (Au), POM (UK), ℞-only (U.S.)
Pharmacokinetic data
Bioavailability	60 to 80% (Oral)
Protein binding	25%
Metabolism	Hepatic (16%)
Elimination half-life	36 to 48 hours (patients with normal renal function) 3.5 to 5 days (patients with impaired renal function)
Excretion	Renal
Identifiers
IUPAC name 4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3- [(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5- [(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl- oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan- 2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl] oxy-12,14-dihydroxy-10,13-dimethyl-1, 2,3,4,5,6,7,8,9,11,12,15,16,17-tetra decahydrocyclopenta[a]phenanthren- 17-yl]-5H-furan-2-one
CAS Number	20830-75-5
PubChem CID	30322
DrugBank	APRD00098
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C41H64O14
Molar mass	780.938 g/mol
Melting point	249.3 °C (480.74 °F)
Solubility in water	64.8 mg/mL (20 °C)

WikiDoc Resources for Digoxin detailed information
Articles
Most recent articles on Digoxin detailed information Most cited articles on Digoxin detailed information Review articles on Digoxin detailed information Articles on Digoxin detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Digoxin detailed information Images of Digoxin detailed information Photos of Digoxin detailed information Podcasts & MP3s on Digoxin detailed information Videos on Digoxin detailed information
Evidence Based Medicine
Cochrane Collaboration on Digoxin detailed information Bandolier on Digoxin detailed information TRIP on Digoxin detailed information
Clinical Trials
Ongoing Trials on Digoxin detailed information at Clinical Trials.gov Trial results on Digoxin detailed information Clinical Trials on Digoxin detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Digoxin detailed information NICE Guidance on Digoxin detailed information NHS PRODIGY Guidance FDA on Digoxin detailed information CDC on Digoxin detailed information
Books
Books on Digoxin detailed information
News
Digoxin detailed information in the news Be alerted to news on Digoxin detailed information News trends on Digoxin detailed information
Commentary
Blogs on Digoxin detailed information
Definitions
Definitions of Digoxin detailed information
Patient Resources / Community
Patient resources on Digoxin detailed information Discussion groups on Digoxin detailed information Patient Handouts on Digoxin detailed information Directions to Hospitals Treating Digoxin detailed information Risk calculators and risk factors for Digoxin detailed information
Healthcare Provider Resources
Symptoms of Digoxin detailed information Causes & Risk Factors for Digoxin detailed information Diagnostic studies for Digoxin detailed information Treatment of Digoxin detailed information
Continuing Medical Education (CME)
CME Programs on Digoxin detailed information
International
Digoxin detailed information en Espanol Digoxin detailed information en Francais
Business
Digoxin detailed information in the Marketplace Patents on Digoxin detailed information
Experimental / Informatics
List of terms related to Digoxin detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information, click here

Digoxin (INN) (Template:IPAEng) is a purified cardiac glycoside extracted from the foxglove plant, Digitalis lanata. Its corresponding aglycone is digoxigenin. Digoxin is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication. Digoxin preparations are commonly marketed under the trade names Lanoxin, Digitek, and Lanoxicaps. It is also available as a 0.05 mg/mL oral solution and 0.25 mg/mL or 0.5 mg/mL injectible solution.

Actions

The main pharmacological effects of digoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects (see below).

Its main cardiac effects are

• A decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter.
• An increase of force of contraction via inhibition of the Na⁺/K⁺ ATPase pump (see below).

Mechanism of action

Digoxin binds to a site on the extracellular aspect of the α-subunit of the Na⁺/K⁺ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na⁺/K⁺ pump leads to increased intracellular Na⁺ levels, which in turn slows down the extrusion of Ca²⁺ by the Na⁺/Ca²⁺ exchange pump that relies on the high Na⁺ gradient. This effect causes an increase in the length of Phase 4 and Phase 0 of the Cardiac Action Potential, which when combined with the effects of Digoxin on the parasympathetic nervous system, lead to a decrease in heart rate. Increased amounts of Ca²⁺ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by digoxin. This leads to increased contractility of the heart. This is a different mechanism from that of catecholamines.

Digoxin also increases vagal activity via its action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias (see below).

Clinical use

Today, the most common indications for digoxin are probably atrial fibrillation and atrial flutter with rapid ventricular response. High ventricular rate leads to insufficient diastolic filling time. By slowing down the conduction in the AV node and increasing its refractory period, digoxin can reduce the ventricular rate. The arrhythmia itself is not affected, but the pumping function of the heart improves owing to improved filling.

The use of digoxin in heart problems during sinus rhythm was once standard, but is now controversial. In theory the increased force of contraction should lead to improved pumping function of the heart, but its effect on prognosis is disputable and other effective treatments are now available. Digoxin is no longer the first choice for congestive heart failure, but can still be useful in patients who remain symptomatic despite proper diuretic and ACE inhibitor treatment. It has fallen out of favor because it was proven to be ineffective at decreasing morbidity and mortality in Congestive Heart Failure. It is shown to increase quality of life, however.

Digoxin is usually given by mouth, but can also be given by IV injection in urgent situations (the IV injection should be slow, heart rhythm should be monitored). The half life is about 36 hours, digoxin is given once daily, usually in 125 μg or 250 μg dosing. In patients with decreased kidney function the half life is considerably longer, calling for a reduction in dosing or a switch to a different glycoside (such as digitoxin which although having a much longer elimination half-life of around 7 days, is mainly eliminated from the body via the liver, and thus not affected by changes in renal function).

Effective plasma levels are fairly well defined, 1-2.6 nmol/l. In suspected toxicity or ineffectiveness, digoxin levels should be monitored. Plasma potassium levels also need to be closely controlled (see side effects below).

Adverse effects

The occurrence of adverse drug reactions is common, owing to its narrow therapeutic index (the margin between effectiveness and toxicity). Adverse effects are concentration-dependent, and are rare when plasma digoxin concentration is <0.8 μg/L. They are also more common in patients with low potassium levels (hypokalemia), since digoxin normally competes with K⁺ ions for the same binding site on the Na⁺/K⁺ ATPase pump.

Common adverse effects (≥1% of patients) include: loss of appetite, nausea, vomiting, diarrhea, blurred vision, visual disturbances (yellow-green halos), confusion, drowsiness, dizziness, nightmares, agitation, and/or depression. Less frequent adverse effects (0.1%–1%) include: acute psychosis, delirium, amnesia, shortened QRS complex, atrial or ventricular extrasystoles, paroxysmal atrial tachycardia with AV block, ventricular tachycardia or fibrillation, heart block but when systematically sought, the evidence for this is equivocal. The pharmacological actions of digoxin usually results in electrocardiogram (ECG) changes, including ST depression or T wave inversion, which do not indicate toxicity. PR interval prolongation, however, may be a sign of digoxin toxicity. Additionally, increased intracellular Ca²⁺ may cause a type of arrhythmia called bigeminy (coupled beats), eventually ventricular tachycardia or fibrillation. The combination of increased (atrial) arrhythmogenesis and inhibited atrio-ventricular conduction (for example paroxysmal atrial tachycardia with A-V block - so-called "PAT with block") is said to be pathognomonic (i.e. diagnostic) of digoxin toxicity.

An often described but rarely seen adverse effect of digoxin is a disturbance of colour vision (mostly yellow and green colour) called xanthopsia. It has been proposed that the painter Vincent Van Gogh's "Yellow Period" may have somehow been influenced by concurrent digitalis therapy.

Digoxin has an interaction with the antimalarial medication Hydroxychloroquine.

Other information

Digoxin has potentially dangerous interaction with verapamil, amiodarone and erythromycin.

In overdose, the usual supportive measures are needed. If arrhythmias prove troublesome, or malignant hyperkalaemia occurs (inexorably rising potassium level due to paralysis of the cell membrane bound ATPase-dependent Na/K pumps), the specific antidote is antidigoxin (antibody fragments against digoxin, trade names of Digibind® and Digifab®). Toxicity can also be treated with higher than normal doses of potassium. Digoxin is not removed by hemo or peritoneal dialysis with enough effectiveness to treat toxicity.

Researchers at Yale University looked at data from an earlier study to see if digoxin affected men and women differently. That study determined that digoxin, which has been used for centuries and makes the heart contract more forcefully, did not reduce deaths overall but did result in less hospitalization.

Researcher Dr. Harlan Krumholz said they were surprised to find that women in the study who took digoxin died more frequently (33%) than women who took a dummy pill (29%). They calculated that digoxin increased the risk of death in women by 23%. There was no difference in the death rate for men in the study.

In the news

Charles Cullen admitted in 2003 to killing as many as 40 hospital patients with overdoses of heart medication—usually digoxin—at hospitals in New Jersey and Pennsylvania over his 16-year career as a nurse. On March 10, 2006 he was sentenced to 18 consecutive life sentences and is not eligible for parole for 397 years.

See also

• Acetyldigoxin
• Cardiac glycoside
• Digitalis
• Digitoxin
• Digoxigenin

Further reading

• Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology, 5th edition. Edinburgh: Churchill Livingstone; 2003. ISBN 0-443-07145-4
• Summary of product characteristics, Digoxin 0,125 mg, Zentiva a.s.
• Lüllmann. Pharmakologie und Toxikologie (15th edition), Georg Thieme Verlag, 2003. ISBN 3-13-368515-5

Template:WikiDoc Sources